Mayo Clinic | Strategic Alliance Partners

The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.

Using biosimilars and generics as well as getting patients connected with manufacturer copay assistance or grant programs can reduce their out-of-pocket costs.

Clayton Irvine, PharmD, MBA, MS, notes that although these options help to lower the cost of care, quick, widespread implementation remains difficult.

Automation and artificial intelligence can also aid significantly in reducing time-consuming tasks and improving efficiency for pharmacists, allowing them more time with patients.

However, the cost of zuranolone makes it challenging to access and justify, given study results comparing it with brexanolone.

More cost effectiveness data is crucial in advocating for better insurance coverage in the United States.

Anatomical alterations result in many downstream changes, such as changes in pH, gastric volume, food intake, surface area for absorption, gastric emptying and transit times, and intestinal enzymes and efflux pumps, among others.

Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV

Roughly one-third of patients with cancer do not achieve adequate pain control.

The American College of Clinical Gynecology recommends consideration of brexanolone or zuranolone in postpartum patients with onset of moderate-to-severe perinatal depression in the third trimester or within 4 weeks postpartum.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the crucial role pharmacists play in providing supportive care for patients with cancer.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Jodi Taraba, PharmD, MS, BCOP, offers insights on the benefits of involving oncology pharmacists in clinical trial research to advance treatment and care for patients with cancer.

Candy Peskey highlights the necessary role of oncology pharmacists in patient care and enrollment in clinical trials.

Scott Soefje highlights how oncology pharmacists can advance patient-centered care and drive innovation in clinical research.

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

Adrijana Kekic, PharmD, a pharmacogenomics clinical specialist with Mayo Clinic in Phoenix, Arizona, discussed current guidelines for pharmacogenomics.

Scott Soefje, PharmD, BCOP, FCCP, FHOPA, MBA, addresses some of the key steps pharmacists should take when conducting a financial analysis for cancer drugs.

A notable revision now includes a dual GIP and GLP-1 receptor agonist (tirzepatide) as an additional option for glycemic management, preferred over insulin.

Tacrolimus is a selective calcineurin inhibitor that exerts inhibitory effects on T-cell proliferation.

Although newly approved, there is some debate regarding the benefits and populations in which sotagliflozin will be the most effective.

Pharmacogenomic information can be used to more selectively choose medications and doses that are more appropriate for each individual.

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with stage 2 T1D.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses the multifaceted role of oncology pharmacists in diverse care settings, emphasizing their collaboration in treatment decisions and adaption in the evolving landscape of cancer care.

Pharmacists' expertise is crucial in educating patients about regulatory changes, helping them navigate alternative formulations, and providing insights into evidence-based choices.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.